Regulations for Implementation of the Drug Administration Law of the People's Republic of China
Decree of the State Council of the People’s Republic of China
No. 360
The Regulations for Implementation of the Drug Administration Law of the People’s Republi c of China are hereby promulgated and shall go into effect as of September 15, 2002.
Premier: Zhu Rongji
August 4, 2002
Regulations for Implementation of the Drug Administration Law of the
People’s Republic of China
Chapter I
General Provisions
Article 1 The Regulations are formulated in accordance with the Drug Administration Law of the People’s Republic of China (hereinafter referred to as the Drug Administration law).
Article 2 The drug regulatory department under the State Council shall establish a national drug testing institute.
The drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government may establish drug testing institutes within its respective administrative area. The plan for the establishment of local drug testing institutes shall be proposed by the drug regulatory department of the people’s government of the province, autonomous region and municipality directly under the Central Government and submitted to th e people’s government of the province, autonomous region and municipality directly under the Central Government for approval.
The drug regulatory department under the State Council and the drug regulatory department of the people’s government of the provi nce, autonomous region or municipality directly under the Central Government may, when necessary, designate any testing institute fulfilling the requirements for drug testing to undertake drug testing.
Chapter II
Control over Drug Manufacturers
Article 3 A Drug Manufacturing Certificate shall be acquired for establishment of a drug manufacturer according to the following procedures:
(1) The applicant shall submit an application to the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government, where the manufacturing site is to be located. The drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government shall, within 30 working days from the date it receives the application, make a review according to the pharmaceutical industry
development programs and policies issued by the State and make a decision on approval or disapproval.
(2) After completion of establishment of the planned manufacturer, the applicant shall apply to the original approving department for acceptance inspection. The original approving department shall, within 30 working days from the date it receives the application, arrange an acceptance inspection according to the requirements for the establishment of such manufacturers set forth in Article 8 of the Drug Administration Law; a Drug Manufacturing Certificate shall be issued to the applicant if the inspection is passed. The applicant shall, by holding the Drug Manufacturing Certificate, register with the administrative department for industry and commerce in accordance with law.
Article 4 Any drug manufacturer that intends to alter the approved items in the Drug Manufacturing Certificate shall, 30 days prior to alteration of any approved items, apply to the original certificate-issuing authority for registration of alteration; no approved items may be altered without approval. The original certificate-issuing authority shall make a decision within 15 working days from the date it receives the application. The application shall, by holding the Drug Manufacturing Certificate with altered items, register the alteration with the administrative department for industry and commerce in accordance with law.
Article 5 The drug regulatory department of the people’s government at or above the provincial level shall organize inspections of drug manufacturers in accordance with the Good Manufacturing Practice for Pharmaceutical Products (GMP) and the measures and schedule for implementing the GMP formulated by the drug regulatory department under the State Council, and issue a certificate to the manufacturer that complies with the GMP. For the manufacturer producing injections or radioactive pharmaceuticals and for that producing
biological products specified by the drug regulatory department under the State Council, the inspection of which shall be conducted by the drug regulatory department under the State Council. The format of GMP certificate shall be uniformly provided for by the drug regulatory department under the State Council.
Article 6 Any newly-established drug manufacturer or manufacturer with newly –built drug manufacturing workshops or newly-added dosage forms for production shall, within 30 days from the date it obtains the approval documents for manufacturing drug or from the date its formal production is approved, apply to the drug regulatory department for GMP certification as required. The drug regulatory department accepting the application shall, within six months from the date it receives the application, organize inspections as to the compliance with the GMP requirements by the applying manufacturer. A certificate shall be issued to the manufacturer if the inspection is passed.
Article 7 The drug regulatory department under the State Council shall set up a database of GMP inspectors. A GMP inspector shall be qualified as required by the drug regulatory department under the State Council. A GMP inspection shall be conducted by a team of inspectors randomly selected from the database of GMP inspectors according to the provisions of the drug regulatory department under the State Council.
Article 8 The valid term of a Drug Manufacturing Certificate is five years. To continue its drug production, the Certificate holder shall, six months prior to the expiry date of the Certificate, apply for the renewal of the Drug Manufacturing Certificate according to the provisions of the drug regulatory department under the State Council.
Where a drug manufacturer terminates its drug production or is closed down, its Drug Manufacturing Certificate shall be withdrawn by the original
certificate-issuing authority.
Article 9 Any drug substance used by a drug manufacturer to produce drug products shall have a drug approval number or an import drug license or a pharmaceutical product license issued by the drug regulatory department under the State Council upon examination, with the exception of Chinese crude drugs and the prepared slices of Chinese crude drugs over which no control by approval number is exercised.
Article 10 In accordance with the provisions in Article 13 of the Drug Administration Law, any drug manufacturer being entrusted with contract production of the drug shall have a GMP certificate corresponding to the contracted drug.
No vaccines, blood products or other drugs specified by the drug regulatory department under the State Council may be contracted for production.
Chapter III
Control over Drug Distributors
Article 11 For establishment of a drug wholesaler, the applicant shall submit an application to the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government, where the planned drug wholesaler is to be located. The drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government shall, within 30 working days from the date it receives the application, make a decision on
approval or disapproval according to the standards for establishment set forth by the drug regulatory department under the State Council. After completion of establishment of the planned wholesaler, the applicant shall apply to the original approving department for acceptance inspection. The original approving department shall, within 30 working days from the date it receives the application, organize an acceptance inspection according to the requirements for establishment of drug distributors set forth in Article 15 or the Drug Administration Law and issue the Drug Supply Certificate to the applicant if the inspection is passed. The applicant shall, with the Certificate, register with the administrative department for industry and commerce in accordance with law.
Article 12 For establishment of a drug retailer, the applicant shall submit an application to the drug regulatory institution of the municipality divided into districts, or to the drug regulatory institution at the county level which is directly set up by the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government, where the planned retailer is to be located. The drug regulatory institution accepting the application shall, within 30 working days from the date it receives the application, make a decision on approval or disapproval after the review according to the provisions of the drug regulatory department under the State Council, taking into consideration the number of permanent residents, territory, transportation and practical needs in the place. After completion of establishment of the planned retailer, the applicant shall apply to the original approving department for acceptance inspections. The original approving department shall, within 15 working days from the date it receives the application, organize acceptance inspections according to the requirements for establishment of drug distributors set forth in Article 15 of the Drug
Administration Law and issue a Drug Supply Certificate if inspections are passed. The applicant shall, with the Certificate, register with the administrative department for industry and commerce in accordance with law.
Article 13The drug regulatory department of the people’s gover nment of the province, autonomous region or municipality directly under the Central Government shall be responsible for the certification of drug distributors. A drug distributor shall, according to the implementing measures and schedule formulated by the drug regulatory department under the State Council, undergo the Good Supply Practice for Pharmaceutical Products (GSP) inspections organized by the local drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government and obtain a GSP certificate. The format of GSP certificate shall be uniformly provided for by the drug regulatory department under the State Council.
Any newly-established drug wholesaler or retailer shall, within 30 days from the date it obtains the Drug Supply Certificate, apply for the GSP certification to the drug regulatory department or institution which has issued it the Drug Supply Certificate. The drug regulatory institution accepting the drug retailer’s application for certification shall, within seven working days from the date it receives the application, transfer the application to the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government, which is responsible for organizing inspections of drug distributors. The drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central government shall, within three months from the date it receives the application, organize inspections of the drug wholesaler or retailer as to its compliance with the GSP according to the provisions of the drug
regulatory department under the State Council and issue a GSP certificate to the drug wholesaler or retailer passing the inspections.
Article 14 A database of GSP inspectors shall be set up by the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government. A GSP inspector shall be qualified as required by the drug regulatory department under the State Council.
A GSP inspection shall be conducted by a team of inspectors randomly selected from the said database according to the provisions of the drug regulatory department under the State Council.
Article 15 The State adopts a classification system for prescription drugs and non-prescription drugs. The State subdivides non-prescription drugs into Class A drugs and Class B drugs according to the level of safety.
Any drug retailer distributing prescription drugs or Class A non-prescription drugs shall have licensed pharmacists or other pharmaceutical technicians whose qualifications are legally recognized. Any retailer distributing Class B non-prescription drugs shall have pharmacy staff members who have passed the examination organized by the local drug regulatory institution of the municipality divided into districts or by the local drug regulatory institution at the county level which is directly set up by the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government.
Article 16 Any drug distributor that intends to alter the approved items in the Drug Supply Certificate shall, 30 days prior to the alteration of any approved items, apply to the original certificate-issuing authority for registration of alteration; no approved items may be altered without approval. The original
certificate-issuing authority shall make a decision within 15 working days from the date it receives the application. The application shall, by holding the Drug Supply Certificate with the altered items, register the alteration with the administrative department for industry and commerce in accordance with law.
Article 17 The valid term of a Drug Supply Certificate is five years. To continue its drug distribution, the Certificate holder shall, six months prior to the expiry date of the Certificate, apply for the renewal of the Drug Supply Certificate according to the provisions of the drug regulatory department under the State Council.
Where a drug distributor terminates its drug distribution or is closed down, its Drug Supply Certificate shall be withdrawn by the original certificate-issuing authority.
Article 18 Where there is no drug retailers at town or country fairs in remote areas with poor communications, the local drug retailers may, after obtaining approval from the local drug regulatory institution of the county (municipality) and being registered with the administrative department for industry and commerce, set up stores at the fairs to sell non-prescription drugs within the approved scope for drug distribution.
Article 19 Drug manufacturers, drug distributors and medical institutions engaged in on-line drug transactions through Internet and the drugs so transacted shall be in conformity with the provisions in the Drug Administration Law and in the Regulations. The measures for administration of on-line drug distribution services shall be formulated by the drug regulatory department under the State Council jointly with the other relevant departments under the State Council.
Chapter IV
Control over Pharmaceuticals in Medical Institutions
Article 20 To establish a pharmaceutical preparation unit in a medical institution, an application shall be submitted to the local health administrative department of the people’s government of the province, autonomous region or municipality directly under the Central Government, and, after being consented upon examination, be presented to the drug regulatory department of the people’s government at the same level for review and approval. Approval shall be given to the medical institution if it passes the review by the said drug regulatory department and a Pharmaceutical Preparation Certificate for Medical Institution shall be issued to it.
The health administrative department and the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government shall, within 30 working days from the dates they receive the application respectively, make their own decisions whether or not to consent or approve the application accordingly.
Article 21 Any medical institution that intends to alter the approved items in the Pharmaceutical Preparation Certificate for Medical Institution shall, 30 days prior to the alteration of any approved items, apply to the original examining and approving departments for registration of alteration according to the provisions in Article 20 of the Regulations; no approved items may be altered without approval. The original examining and approving departments shall make their own decisions within 15 working days from the dates they receive the application respectively.
Any medical institution which intends to add new dosage forms or change dispensing sites shall, after passing the acceptance inspection by the local drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government, go through the registration of alteration of the Pharmaceutical Preparation Certificate for Medical Institution according to the provisions in the preceding paragraph.
Article 22 The valid term of a Pharmaceutical Preparation Certificate for Medical institution is five years. To continue dispensing a pharmaceutical preparation, the medical institution shall, six month prior to the expiry date of the Certificate, apply for the renewal of the Pharmaceutical Preparation Certificate for Medical Institution according to the provisions of the drug regulatory department under the State Council.
Where a medical institution terminates dispensing Pharmaceutical Preparations or is closed down, its Pharmaceutical Preparation Certificate for Medical Institution shall be withdrawn by the original certificate-issuing authority.
Article 23 To dispense a pharmaceutical preparation, the medical institution shall submit the dossier and samples according to the provisions of the drug regulatory department under the State Council, and the pharmaceutical preparation may only be dispensed after being approved by the local drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government and being issued a pharmaceutical preparation approval number.
Article 24 No pharmaceutical preparations dispensed by medical institutions may be marketed or marketed in disguised forms, nor may any advertisement of such pharmaceutical preparations be released.
When a major disaster, epidemic situation or any other emergency occurs, or there is an urgent need clinically but no supply of the needed drug in market, the pharmaceutical preparations dispensed by a medical institution may be subject to transfer allocation and use by other designated medical institutions within a specified time limit, upon approval by the drug regulatory department under the State Council or by the drug regulatory department of the people’s government of a province, autonomous region or municipality directly under the Central Government.
Transfer allocation and use of special pharmaceutical preparations regulated by the drug regulatory department under the State Council, and the transfer allocation and use of pharmaceutical preparations dispensed by medical institutions among provinces, autonomous regions, or municipalities directly under the Central Government shall be subject to the approval by the drug regulatory department under the State Council.
Article 25 Pharmacy personnel of medical institutions who check and dispense prescriptions shall be the pharmaceutical technicians whose qualifications are legally recognized.
Article 26 When purchasing drugs, medical institutions shall keep the authentic and complete records. In purchase records shall be indicted the adopted name of the drug in China, dosage form, strength, batch number, date of expiry, manufacturer, supplier, purchase volume, purchase price, date of purchase and other items specified by the drug regulatory department under the State Council.
Article 27 Drugs provided to patients by medical institutions shall be within the scope of diagnoses and treatments and dispensed according to the prescriptions of licensed doctors or licensed assistant doctors.
The scope of drugs purchased and provided to patients by family planning technical service institutions shall be in conformity with the scope of services approved and the drugs shall be dispensed according to the prescriptions of licensed doctors or licensed assistant doctors.
Out-patient departments, clinics and any other medical institutions, which are set up by individuals, may not purchase or provide drugs other than those commonly used and those for emergency treatment. The range and category of the drugs commonly used and those for emergency treatment shall be determined by the local health administrative department of the people’s government of the province, autonomous region, or municipality directly under the Central Government jointly with the drug regulatory department at the same level.
Chapter V
Control over Drugs
Article 28 Institutions for non-clinical safety evaluation and study of drugs shall implement the Good Laboratory Practice for Non-Clinical Laboratory Studies (GLP) and institutions for drug clinical trial shall implement the Good Clinical Practice (GCP). The GLP and GCP shall be formulated by the drug regulatory department under the State Council through respective consultation with the science and technology administrative department under the State Council and the health administrative department under the State Council.
Article 29 Clinical trials, manufacturing or importation of drugs shall be in conformity with the provisions in the Drug Administration Law and in the Regulations, and shall be reviewed and approved by the drug regulatory department under the State Council. The drug regulatory department under the State Council may authorize the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government to conduct site inspection of research and development conditions of the drugs being applied, to conduct preliminary review of the submitted dossier, and to test the pilot samples. The specific measures therefore shall be formulated by the drug regulatory department under the State Council.
Article 30 Any clinical trial to be conducted for research and development of a new drug shall be subject to the approval by the drug regulatory department under the State Council in accordance with the provisions in Article 29 of the Drug Administration Law.
When an application for conducting clinical trials is approved by the drug regulatory department under the State Council, the applicant shall select institutions for clinical trials from the lawfully certified ones to conduct the trials, and make a report thereof to the drug regulatory department and health administrative department under the State Council for the record.
Prior to the drug clinical trial, the institution for drug clinical trial shall provide the subjects or their guardians with the truthful information on the trial, and obtain a written informed consent
Article 31 For production of a drug admitted by national drug standards, an application shall, in accordance with the provisions of the drug regulatory
department under the State Council, be submitted to the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government or to the drug regulatory department under the State Council, and the relevant technical data and supporting documents shall be provided. The drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government shall, within 30 working days from the date it receives the application, review and make comments, and report the matter to the drug regulatory department under the State Council for review while notifying the applicant of its comments. If all the requirements are fulfilled upon review, a drug approval number shall be issued by the drug regulatory department under the State Council.
Article 32 Where a drug is produced according to an interim standard, an application shall be submitted for formalization of the standard three months prior to the expiry date of the interim standard according to the provisions of the drug regulatory department under the State Council; the drug regulatory department under the State Council shall, within 12 months from the expiry date of the interim standard, review and approve the interim standard as formal one if it fulfills the requirements for the formalization set forth by the drug regulatory department under the State Council. Where an applicant does not make such an application or the original interim standard fails to fulfill the requirements for the formalization, the drug regulatory department under the State Council shall withdraw the interim standard and the approval number for drug production issued on the basis of the said interim standard.
Article 33 For alteration of any items indicated in the approval documents and their attachments for new drug research and development, production or importation of a drug, a supplementary application shall be submitted to the
drug regulatory department under the State Council; if all the requirements are fulfilled upon review, an approval shall be given by the drug regulatory department under the State Council.
Article 34 The drug regulatory department under the State Council may, based on the needs for protection of public health, set an observation period of not more than five years for a new drug produced by a drug manufacturer; and no approval shall be given to any other manufacturer to produce or import the said drug during the observations period.
Article 35 The State protects undisclosed data of drug study and others which are independently acquired and submitted by drug manufacturers or sellers to obtain production or marketing approval of the drugs in question which contain new chemical entities. No one may make unfair commercial use of the said data.
Within six years from the date a drug manufacturer or seller obtains the approval documents for producing or marketing a drug containing new chemical entities, if any other applicant uses the data mentioned in the preceding paragraph to apply for approval for production or marketing of the drug in question without permission of the original applicant who has obtained the approval, no approval may be given to any other applicant by the drug regulatory department except that the data submitted are acquired independently.
No drug regulatory department may disclose the data set forth in the first paragraph of this Article except
(1) for the need of public interests; or
(2) where steps are taken to ensure that the data are protected against unfair commercial use.
Article 36 Any drug applied to be imported shall be the one obtained marketing authorization in the country or region of manufacturing. A drug without such an authorization may be approved of its importation in accordance with the provisions in the Drug Administration Law and in the Regulations, provided that its safety, efficacy and clinical needs have been confirmed by the drug regulatory department under the State Council.
For importation of a drug, an application for registration shall be made according to provisions of the drug regulatory department under the State Council. A drug may only be imported after an Import Drug License is given if it is produced by a foreign manufacturer, or a Pharmaceutical Product License is given if it is produced by a manufacturer in Hong Kong, Macao or Taiwan of China.
Article 37 Any medical institution that urgently needs to import a small amount of drugs shall, with a Practicing License of Medical Institution, submit an application to the drug regulatory department under the State Council, and the drugs in question may only be imported upon approval. Such import drugs shall only be used in the designated medical institution for specified purpose.
Article 38 After import drugs arrive at the port, the drug importer shall file a record with the local drug regulatory department in the place where the port is located with the Import Drug License or Pharmaceutical Product License, the original copy of the certificate or origin, duplicate copy of the purchase contract, packing list, bill of freight, shipping invoice, certificate of analysis for the release of drugs by the manufacturer, inset sheet and other documents. The said drug regulatory department shall review the documents submitted and issued a Drug Import Note if they comply with the requirements. The drug importer shall, with
the Drug Import Note, complete the formalities for customs declaration and clearance with the Customs.
The drug regulatory department in the place where the port is located shall notify the drug testing institution to conduct sampling and testing of the import drugs on each batch basis with the exception of the circumstances set forth in Article 41 of the Drug Administration Law.
Article 39 Vaccines, blood products, diagnostic reagents in vitro for blood donor screening and other biological products regulated by the drug regulatory department under the State Council shall be subject to testing or review for approval according to the provisions of the drug regulatory department under the State Council before being marketed or imported; any product that fails in testing or has not been approved shall not be marketed or imported.
Article 40 The State encourages cultivation of Chinese crude drugs. Control through approval number shall be exercised over the Chinese crude drugs that can be cultivated or raised on a large scale and in an intensified way and whose quality can be controlled and fulfills the requirements laid down by the drug regulatory department under the State Council.
Article 41 The drug regulatory department under the State Council shall
re-evaluate the drugs approved for production and marketing and, on the basis of the re-evaluation results, may take measures to order the revision of insert sheet or suspension of production, marketing or use of a drug, or withdraw the approval documents of drugs with serious adverse reaction or harmful to human health due to other reasons.
Article 42 The valid term of a drug approval number, Import Drug License and Pharmaceutical Product License issued by the drug regulatory department
under the State Council is five years. To continue its drug production or importation, the applicant shall submit a re-registration application six months prior to the expiry date. When making re-registration of a drug, the applicant shall submit the relevant data according to the provisions of the drug regulatory department under the State Council. If no application for the re-registration of a drug is made upon expiration of the valid term, or the application fails to comply with the provisions on re-registration of the drug regulatory department under the State Council upon review, the drug approval number, Import Drug License or Pharmaceutical Product License shall be withdrawn.
Article 43 No contents involving prevention, treatment or diagnosis of human diseases shall be included in the package, label or insert sheet and the related promotional materials for promoting a non-drug product, except as otherwise provided by laws or administrative regulations.
Chapter VI
Control over Drug Packaging
Article 44 Immediate packaging materials and containers used by drug manufacturers shall fulfill the requirements for medicinal use and the standards for ensuring human health and safety, and be subject to registration upon approval by the drug regulatory department under the State Council.
The drug regulatory department under the State Council shall be responsible for working out and issuing the measures for control over immediate packaging materials and containers, the product directories and the requirements and standards for medicinal use.
Article 45 Packaging materials and containers selected for production of prepared slices of a Chinese crude drug shall accommodate to drug properties. No prepared slices of a Chinese crude drug may be marketed whose package fails to conform to regulations. A label shall be printed on or attached to the package of prepared slices of a Chinese crude drug.
On the label of prepared slices of a Chinese crude drug shall be indicated the name of the drug, specifications, origin or production, manufacturer, product batch number and production date; if the said drug is controlled by approval number, the drug approval number shall also be indicated.
Article 46 The package, label and insert sheet of a drug shall be printed in accordance with the provisions in Article 54 of the Drug Administration Law and those formulated by the drug regulatory department under the State Council.
The trade name of a drug shall conform to the provisions of the drug regulatory department under the State Council.
Article 47 The immediate packaging materials and containers, used by medical institutions for dispensing pharmaceutical preparations, as well as the labels and insert sheets thereof, shall conform to the provisions in Chapter VI of the Drug Administration Law and the relevant provisions in the Regulations, and be subject to approval by the drug regulatory department of the people’s government of the province, autonomous region or municipality directly under the Central Government.
Chapter VII
Control over Drug Pricing and Advertising
“的、地、得”的用法和区别 导入（进入美妙的世界啦~） “的、地、得”口诀儿歌 的地得，不一样，用法分别记心上， 左边白，右边勺，名词跟在后面跑。 美丽的花儿绽笑脸，青青的草儿弯下腰， 清清的河水向东流，蓝蓝的天上白云飘， 暖暖的风儿轻轻吹，绿绿的树叶把头摇， 小小的鱼儿水中游，红红的太阳当空照， 左边土，右边也，地字站在动词前， 认真地做操不马虎，专心地上课不大意， 大声地朗读不害羞，从容地走路不着急， 痛快地玩耍来放松，用心地思考解难题， 勤奋地学习要积极，辛勤地劳动花力气， 左边两人双人得，形容词前要用得， 兔子兔子跑得快，乌龟乌龟爬得慢， 青青竹子长得快，参天大树长得慢， 清晨锻炼起得早，加班加点睡得晚， 欢乐时光过得快，考试题目出得难。 知识典例（注意咯，下面可是黄金部分！） 的、地、得 “的”、“地”、“得”的用法区别本是中小学语文教学中最基本的常识，但在使用中也最容易发生混淆，再加上一段时间里，中学课本中曾将这三个词的用法统一为“的”，因此造成了很多人对它们的用法含混不清进而乱用一通的现象。
一、“的、地、得”的基本概念 1、“的、地、得”的相同之处。 “的、地、得”是现代汉语中高频度使用的三个结构助词，都起着连接作用；它们在普通话中都读轻声“de”，没有语音上的区别。 2、“的、地、得”的不同之处。 吕叔湘、朱德熙所著《语法修辞讲话》认为“的”兼职过多，负担过重，而力主“的、地、得”严格分工。50 年代以来的诸多现代汉语论著和教材，一般也持这一主张。从书面语中的使用情况看，“的”与“地”、“得”的分工日趋明确，特别是在逻辑性很强的论述性、说明性语言中，如法律条款、学术论著、外文译著、教科书等，更是将“的”与“地”、“得”分用。 “的、地、得”在普通话里都读轻声“de”，但在书面语中有必要写成三个不同的字：在定语后面写作“的”，在状语后面写作“地”，在补语前写作“得”。这样做的好处，就是可使书面语言精确化。 二、“的、地、得”的用法 1、的——定语的标记，一般用在主语和宾语的前面。“的”前面的词语一般用来修饰、限制“的”后面的事物，说明“的”后面的事物怎么样。结构形式一般为：形容词、名词（代词）+的+名词。如： ①颐和园(名词)的湖光山色（主语）美不胜收。 ②她是一位性格开朗的女子(名词，宾语)。 2、地——状语的标记，一般用在谓语（动词、形容词）前面。“地”前面的词语一般用来形容“地”后面的动作，说明“地”后面的动作怎么样。结构方式一般为：形容词（副词）+地+动词（形容词）。如： ③她愉快(形容词)地接受(动词，谓语)了这件礼物。 ④天渐渐(时间副词)地冷(形容词，谓语)起来。 3、得——补语的标记，一般用在谓语后面。“得”后面的词语一般用来补充说明“得”前面的动作怎么样，结构形式一般为：动词（形容词）+得+副词。如： ⑤他们玩(动词，谓语)得真痛快(补语)。
英语单词惯用法集锦 习惯接动词不定式的动词（V to inf) adore(vi极喜欢) dread （vt.不愿做，厌恶）plan 计划 afford（+to,vt有条件，能承担）endeavour （vt，竭力做到，试图或力图）prefer（vt.宁可；宁愿(选择)；更喜欢）agree 同意endure(忍受.cannot ~ to) prepare准备 aim (vi[口语]打算：) engage (vi.保证，担保；) presume(vt.冒昧；敢于[用于第一人称时为客套话]：) appear (vi.似乎；显得) essay(vt.尝试，试图) pretend(vt.自命；自称；敢于；妄为) apply （申请）expect（期望，希望）proceed（开始，着手，）arrange （vi.做安排，(事先)筹划）fail （vt.未做…；疏忽)promise(许诺，保证做 ask （要求）forget （vt. 忘记）purpose （vt.决心，打算） beg （vt.正式场合的礼貌用语]请(原谅)，请(允许)：I beg to differ.恕我不能赞同）guarantee（保证，担保）refuse（拒绝）bear 承受，忍受hate（[口语]不喜欢；不愿意；）regret （vt. 抱歉；遗憾）begin help （有助于，促进）remember（记住） bother （vi.通常用于否定句]麻烦，费心）hesitate（vi.犹豫；有疑虑，不愿）scheme（策划做）care （vt.想要；希望；欲望[后接不定式，常用于否定、疑问及条件句中]）hope （vt.希望，盼望，期待）seek（vt.谋求，图谋[后接不定式]） cease （停止; 不再(做某事)[正式] intend （打算；想要）seem（似乎，好像[后接不定式或从句]；觉得像是，以为[ choose （意愿；选定；决定）itch start开始claim （vt. 主张；断言；宣称） continue （继续）like 喜欢swear（vt.起誓保证；立誓要做(或遵守） dare （vt.敢，敢于，勇于，胆敢）long（vi.渴望；热望；极想） decline（vt.拒绝，拒不(做、进入、考虑等) manage（设法完成某事）threaten（vt.威胁，恐吓，恫吓）deign （屈尊做）mean（有意[不用进行时）trouble（vi.费心，费神；麻烦）demand（vi.要求，请求：）need （需要）try（设法做） deserve (应得) neglect (疏忽) undertake(承诺,答应，保证) desire （希望渴望）offer（表示愿意(做某事)，自愿；）venture（冒险(做某事））determine（vi.决心，决意，决定，）omit （疏忽，忘记）want 想要 die （誓死做）pine （渴望）wish （希望） 习惯接“疑问词+动词不定式”的动词（有时也包括VN wh-+to do) advise 建议explain 解释perceive 觉察，发觉 answer 答复find 得知，察觉persuade 说服，劝说；使某人相信 ask 询问，问forget 忘记phone 打电话 assure 保证guess 臆测，猜度pray 祈祷 beg 请求，恳求hear 小心聆听（法庭案件）promise 允诺 conceive 想象，设想imagine 以为，假象remember记得 consider 考虑，思考indicate 暗示remind 提醒，使想起 convince 使相信inform告知通知instruct告知，教导 see 看看，考虑，注意decide 解决，决定know 学得，得知 show 给人解释；示范；叙述；discover发现；知道learn 得知，获悉 signal以信号表示doubt 怀疑，不相信look 察看；检查；探明 strike 使想起；使突然想到；使认为suggest 提议，建议tell 显示，表明；看出，晓得；warn 警告，告诫think 想出；记忆，回忆；想出，明白wonder 纳闷，想知道 wire 打电报telegraph 打电报 习惯接动名词的动词（包括v+one’s/one+v+ing) acknowledge 认知，承认…之事实escape免除，避免omit疏忽，忽略 admit 承认，供认excuse 原谅overlook 放任，宽容，忽视adore （非正式）极为喜欢fancy 构想，幻想，想想postpone 延期，搁置 advise 劝告，建议finish完成prefer较喜欢 appreciate 为…表示感激(或感谢)forbid 不许，禁止prevent预防 avoid 逃避forget 忘记prohibit 禁止，妨碍
in on at 区别用法 妙计口诀 1.早、午、晚要用in， at黎明、午夜、点与分。 年、月、年月、季节、周， 阳光、灯、影、衣、帽用in。 将来时态in...以后， 小处at大处in。 有形with无形by， 语言、单位、材料in。 特征、方面与方式， 心情成语惯用in。 介词at和to表方向， 攻击、位置、恶、善分。 2.日子、日期、年月日，星期加上早、午、晚， 收音、农场、值日on，关于、基础、靠、著论。 着、罢、出售、偷、公、假，故意、支付、相反，准。 特定时日和“一……就”，on后常接动名词。 年、月、日加早、午、晚，of之前on代in。 步行、驴、马、玩笑on，cab，carriage则用in。 at山脚、门口、在当前，速、温、日落、价、核心。 如大体掌握上面介词用法口诀，就不易出错。下面对该口诀分别举例帮助你理解消化。 <1.>关于时间 早、午、晚要用in in the evening 在晚上 in the day 在白天 例： in the afternoon 在下午 in the morning 在早上 at黎明、午、夜、点与分 例 at dawn /at daybreak 在黎明时候 at night 在夜间 at noon 在中午 at midnight 在午夜 （以上短语都不用冠词）
at nine o'clock 在9点钟 at half past ten 在10点半 at ten thirty a.m. 在上午10点30分 at the weekend 在周末 at a quarter to two 1点45分 <2.>关于年、月、年月、季节、周 即在“来年”，在“某月”，在“某年某月” 但在某年某月某日则用on ，在四季，在第几周等都要用in。 in 1927 在1927年 in March 在三月 in December 1986 在1986年12月 in July l984 在1984年7月 in the first week of this semester这学期的第一周 in the third week 在第三周 in spring 在春季 <3.>关于日子、日期、年月日，星期加上早午晚 以下皆用on on October the first 1949 1949年10月1日 on May the first 5月1日 on the sixteenth 16号 on the second of January /on January the second 1月2日 on a summer evening 在夏天的一个夜晚 on New Year's Day 在元旦 on my birthday 在我的生日 on winter day 在冬天 on December 12th 1950 l950年12月12日 on Sunday 在星期天 on Tuesday morning 星期二早晨 但last night 昨夜；in the evening 在晚上 on time准时，in time及时，等则不同。 【注】in the Christmas holidays在圣诞节假期 in the eighteenth century 在十八世纪 in ancient times 在古代 in earlier times 在早期 in modern times 在现代，则用in，at the present time 现在，at the present day当今则用at。 <4.>关于年月日，加早午晚，of之前on代in on the morning of 18th 18日早晨 On the eve of their departure在临行前夕 <5.>阳光、灯、影、衣、冒 in
“的、地、得”用法分析及练习（后附答案） 一、的、地、得用法分析： “的”后面跟的都是表示事物名称的词或词语，如：敬爱的总理、慈祥的老人、戴帽子的男孩、珍贵的教科书、鸟的天堂、伟大的祖国、有趣的情节、优雅的环境、可疑的情况、团结友爱的集体、他的妈妈、可爱的花儿、谁的橡皮、清清的河水...... “地”后面跟的都是表示动作的词或词语，如：高声地喊、愉快地唱、拼命地逃、疯狂地咒骂、严密地注视、一次又一次地握手、迅速地包围、沙沙地直响、斩钉截铁地说、从容不迫地申述、用力地踢、仔细地看、开心地笑笑......” “得”前面多数是表示动作的词或词语，少数是形容词；后面跟的都是形容事物状态的词或词语，表示怎么怎么样的，如：走得很快、踩得稀烂、疼得直叫唤、瘦得皮包骨头、红得发紫、气得双脚直跳、理解得十分深刻、乐得合不拢嘴、惊讶得目瞪口呆、大得很、扫得真干净、笑得多甜啊...... 二、的、地、得用法补充说明： 1、如果“de”的后面是“很、真、太”等这些词，十有八九用“得”。 2、有一种情况，如“他高兴得一蹦三尺高”这句话里，后面的“一蹦三尺高”虽然是表示动作的，但是它是来形容“高兴”的程度的，所以也应该用“得”。
三、的、地、得用法总结： 1、“的”前面的词语一般用来修饰、限制“的”后面的事物，说明“的”后面的事物怎么样。结构形式一般为：修饰、限制的词语+的+名词。 2、“地”前面的词语一般用来形容“地”后面的动作，说明“地”后面的动作怎么样。结构方式一般为：修饰、限制的词语+地+动词。 3、“得”后面的词语一般用来补充说明“得”前面的动作怎么样，结构形式一般为：动词（形容词）+得+补充、说明的词语。 四、的、地、得用法例句： 1. 蔚蓝色的海洋，波涛汹涌，无边无际。 2. 向日葵在微风中向我们轻轻地点头微笑。 3. 小明在海安儿童公园玩得很开心。 五、“的、地、得”的读音： “的、地、得”是现代汉语中高频度使用的三个结构助词，都起着连接作用；它们在普通话中都各自有着各自的不同的读音，但当他们附着在词，短语，句子的前面或后面，表示结构关系或某些附加意义的时候都读轻声“de”，没有语音上的区别。 但在书面语中有必要写成三个不同的字，这样可以区分他们在书面语用法上的不同。这样做的好处，就是可使书面语言精确化。
的、地、得的用法和区别 的、地、得的用法和区别老班教育 一、的、地、得的基本概念 1、的、地、得的相同之处。 的、地、得是现代汉语中高频度使用的三个结构助词，都起着连接作用；它们在普通话中都读轻声de，没有语音上的区别。 2、的、地、得的不同之处。 吕叔湘、朱德熙所著《语法修辞讲话》认为的兼职过多，负担过重，而力主的、地、得严格分工。50 年代以来的诸多现代汉语论著和教材，一般也持这一主张。从书面语中的使用情况看，的与地、得的分工日趋明确，特别是在逻辑性很强的论述性、说明性语言中，如法律条款、学术论著、外文译著、教科书等，更是将的与地、得分用。 的、地、得在普通话里都读轻声de，但在书面语中有必要写成三个不同的字：在定语后面写作的，在状语后面写作地，在补语前写作得。这样做的好处，就是可使书面语言精确化。 二、的、地、得的用法 （一）、用法 1、的——定语的标记，一般用在主语和宾语的前面。的前面的词语一般用来修饰、限制的后面的事物，说明的后面的事物怎么样。 结构形式一般为：形容词、名词（代词）+的+名词。如： 颐和园(名词)的湖光山色（主语）美不胜收。 她是一位性格开朗的女子(名词，宾语)。 2、地——状语的标记，一般用在谓语（动词、形容词）前面。地前面的词语一般用来形容地后面的动作，说明地后面的动作怎么样。 结构方式一般为：形容词（副词）+地+动词（形容词）。如： 她愉快(形容词)地接受(动词，谓语)了这件礼物。 天渐渐(时间副词)地冷(形容词，谓语)起来。 3、得——补语的标记，一般用在谓语后面。得后面的词语一般用来补充说明得前面的动作怎么样。 结构形式一般为：动词（形容词）+得+副词。如： 他们玩(动词，谓语)得真痛快(补语)。 她红(形容词，谓语)得发紫(补语)。 （二）、例说 的，一般用在名词和形容词的后面，用在描述或限制人物、事物时，形容的词语与被形容的词语之间，表示一种描述的结果。如：漂亮的衣服、辽阔的土地、高大的山脉。结构一般为名词（代词或形容词）+的+名词。如，我的书、你的衣服、他的孩子，美丽的景色、动听的歌曲、灿烂的笑容。 地，用法简单些，用在描述或限制一种运动性质、状态时，形容的词语与被形容的词语之间。结构通常是形容词+地+动词。前面的词语一般用来形容后面的动作。一般地的后面只跟动词。比如高兴地跳、兴奋地叫喊、温和地说、飞快地跑；匆匆地离开；慢慢地移动......... 得，用在说明动作的情况或结果的程度时，说明的词语与被说明的词语之间，后面的词语一般用来补充和说明前面的情况。比如。跑得飞快、跳得很高、显得高雅、显得很壮、馋得直流口水、跑得快、飞得高、走得慢、红得很……得通常用在动词和形容词（动词之间）。
1、keep ①keep + 形容词表示“保持” Please keep quite. 请保持安静。 ②keep + 宾语+ 形容词（或介词短语）表示“把……保持在某一状态” We must do everything we can to keep the air clean. 我们必须尽一切所能保持空气清洁。 ③keep sb doing sth 表示“让某人做某事” ——只能用现在分词作宾语补足语，不能用不定式。 He kept us waiting for two hours. 他让我们等了两个小时。 He kept us to wait for two hours. (错误) ④keep on doing sth和keep doing sth 表示“继续做某事，反复做某事”，可换用。 但keep on doing 更强调动作的反复性或做事人的决心。 He keeps on phoning me, but I don’t want to talk to him. Though he failed 3 times, he kept on trying. 他老是给我打电话，但我不想同他讲话。虽然他已失败了3次，但他仍继续干下去。 keep doing sth 经常用于静态动词。 He kept lying in bed all day long. 他整天都躺在床上。 ⑤keep …from doing sth 表示“阻止，使免于” He kept them from fishing in the lake. 他不让他们在那个湖里捕鱼。 2、may not / mustn’t / needn’t / wouldn’t ①may not be 是may be的否定式，意为“可能不是，也许不是” He may be there.他可能在那里。He may not be there.他可能不在那里。 ②must 意为“必须”，mustn’t 意为“千万不可，绝对不可” 所以Must we/I ……?的否定回答要用needn’t—意为“不必” -Must we get there before 11 o’clock？ -No, we needn’t. ③wouldn’t = would not 意为“不会，不愿” I wouldn’t say no. 3、do ①do表示“做”，做某事，常指某种不具体的活动；make表示“制作”，指做出某种具体的东西。
at, in与on的用法区别 1. 表示时间，注意以下用法： ①表示时间的某一点、某一时刻或年龄等用at： I get up at six in the morning. 我早上六点钟起床。 He got married at the age of 25. 他25 岁结婚。 ②泛指一般意义的上午、下午或晚上以及月或年等较长的时间，一般用in：We watch TV in the evening. 我们晚上看电视。 He went to Japan in 1946. 他于1946 去了日本。 ③若表示星期几或某一特定的日期，则用on： He left here on the fifth of May. 他于5 月5 日离开这儿。 2. 表示地点、场所、位置等，注意以下用法： ①表示某一点位置，用at： We live at No 87 Beijing Road. 我们住在北京路87 号。 The hospital is at the end of the street. 医院在这条街的尽头。 与名词所有格连用表示地点，也用at。如： at my sister’s 在我姐姐家 at the doctor’s 在医务室 ②表示空间或范围，用in： What’s in the box? 这盒子里有什么? He lives in Paris with his wife. 他同他妻子住在巴黎。 但有时两者可换用：
The meeting was held at [in] the hotel. 会议在宾馆举行。 ③at与in的另一个区别是：at多用于指较小的地方，而in多用于指较大的地方：in Shanghai 在上海at the station 在车站 ④介词on 用于地点，主要指在某物的表面： What’s on the table? 桌上有什么? There’s a wallet lying on the ground. 地上有个钱包。 【注】在少数搭配中，也用介词on： He works on a farm. 他在农场工作。 3. 在某些搭配中，三者的区别与英国英语和美国英语有关： in the street (英) / on the street (美) 在街上 in the road (英) / on the road (美) 在路上 in the team (英) / on the team (美) 在这个队 at the weekend (英) / on the weekend (美) 在周末 at weekends (英) / on weekends (美) 在周末 4. 有时三者的差别与搭配习惯和用法有关： in bed / on the bed 在床上 in the tree (多指树外之物) / on the tree (多指树本身之物) 在树上
《“的、地、得”的用法》语文微课教案 一、教学背景 在语言文字规范化大背景下，帮助学生解决应用“的地得”的疑惑与困难。 二、设计思路 针对学生对于“的地得”的误用与忽视展开教学，规范结构助词“的地得”的使用。按照“问题的提出、问题的分析、问题的解决”的思路展开教学，总结归纳优化的方式方法。 三、教学目标 1、知道“怎么样的什么、怎么样地干什么、干得怎么样”三种固定搭配。 2、掌握“的、地、得”的区别与联系。 3、运用小儿歌“动前土、名前白、行动后面双人来”的口诀帮助正确使用“的、地、得”。 四、教学重难点 1、知道“的、地、得”的区别。 2、在实际情境中正确运用“的、地、得”。 五、教学时间 8分钟微课堂 六、教学适用对象 义务教育九年制内的学生 七、教学准备
多媒体课件、录屏软件 八、教学设计与过程 开场白： 同学们好！今天我们一起来学习“的、地、得”的正确用法。首先我们来了解一下它们的区别。 1、相同之处：原来它们都是念轻声“de”，都是结构助词，起连接作用。 2、不同之处：在书面语中要写成三个不同的字，而且它们的搭配及用法也各不相同。 （1）怎么样的什么 （2）怎样样地干什么 （3）干得怎么样 下面我们就来学习一下它们的正确用法。 白勺“的”的结构是用“形容词或名词或代词+的+名词”来表示，而我们最常见，用得最多的还是“形容词+的+名词”的结构。 而土也“地”的用法可以用“形容词+地+动词”的结构来表示。 双人“得”是用“动词+得+形容词”的结构来表示 3、练习巩固 （1）形近区分 静静（的）河面静静（地）写字欢乐（的）山谷
欢乐（地）歌唱满意（地）点头满意（的）作品 （2）类别区分 1）跑（得）飞快飞快（地）跑 2）愉快（的）旅行旅行（得）愉快 3）强烈（的）渴望强烈（地）渴望 （3）综合杂糅 小雏鹰飞到大树的上方，高兴地喊起来：“我真的会飞啦！而且飞（得）很高呢！” 小结：能填对这个句子的你肯定就已经学会它们的用法了！ 4、特殊情况 质疑：假如遇到特殊情况怎么办呢？ 我从书包里拿出书交给她们，她们高兴得．围着我跳起舞来。（出自二年级上册《日记两则》） （1）质疑：为什么这里要使用“得”呢？ （2）释疑：原来这里强调的是心情，动词在后，形容词在前，相当于后置，“得”修饰“跳舞”而非“围”。现在你明白了吧？ 5、小结归纳： 怎么样，你们学会了吗？为了让同学们能够更快的记住它们的用法，老师送给大家一首口诀来帮助你们熟记三个“的”的正确使用方法：动前土、名前白、行动后面双人来。
一动词加-ing 的情况 consider, suggest/advise,look forward to, excuse/pardon admit,delay/put off,fancy avoid,miss,keep/keep on,practise deny,finish,enjoy/appreciate forbid,imagine,risk can't help,mind,allow/permit,escape 考虑建议盼原谅, 承认推迟没得想. 避免错过继续练, 否认完成就欣赏. 禁止想象才冒险, 不禁介意准逃亡. 如：建议：advise,suggest,冒险:risk,献身:devote oneself to 二动词后加doing 和加to do sth. 意思不一样的情况 ①remember doing指记住过去做过的事，remember to do指记住将来要做的事，表示“不要忘记”。 ②forget doing表示忘记过去做过的事，forget to do表示“没有想起做某事”。 ③mean doing表示“意味着做某事”，mean to do表示“打算做某事”。 ④regret doing表示对已做过的事感到后悔，regret to do表示对将要做的事表示遗憾。 ⑤stop doing表示“停止做某事”，stop to do是停止做正在做的事以便去做另外一件事，这里的to do不是stop的宾语而是stop的目的状语。 ⑥try doing表示“尝试做某事”，try to do表示“设法、试图做某事”。 ⑦go on doing表示继续做同一件事，go on to do表示做完一件事后，接下去做另外一件事。 三动词后加to do sth. afford负担得起agree同意appear似乎，显得arrange安排 ask问attempt企图beg请求begin开始 choose选择claim要求decide决定demand要求 desire愿望determine决定expect期望fail不能 forget忘记happen碰巧hate憎恨，厌恶hesitate犹豫 hope希望intend想要learn学习long渴望 love爱manage设法mean意欲，打算need需要 neglect忽视offer提供omit忽略，漏other扰乱；烦恼
pretend三种易混淆不定式的用法 今天给大家带来了pretend三种易混淆不定式的用法，我们一起来学习吧，下面就和大家分享，来欣赏一下吧。 pretend三种易混淆不定式的用法 1. pretend to do sth .这个短语的意思是假装(将要)去做什么事情，适用于将来时态动作将来假装要去做但不一定去做的状态。 举例: If youpretend to know what you dont know，youll only make afool of yourself.不懂装懂就会闹笑话。(suri的回答) Child pretend to be mother and father in kindergarten.孩子在幼稚园里面假扮父亲和母亲(表将来)(JasoOon的回答) 2. pretend to have done sth .这个短语的意思是假装已经做过了某事，强调事情的一个完成的状态，侧重于假装的事情已经做好了。 举例:I pretend tohave seen nothing，but I cant.我假装自己没有看到任何东西，但是我做不到(侧重于一个完成时态，已经试图去假装没有看到)
she pretended to have finished the homeworkwhen she went out and played.当她出门玩的时候她假装自己已经完成了家庭作业。(假装做作业这个动作已经在出门玩之前做完了)(JasoOon的回答)以及怀陌的回答:When the teacher came in，he pretended to havefinished the homework.当老师进来的时候他假装自己已经完成家庭作业了，两者有异曲同工之妙。 3. pretendtobe doing sth 这个短语的意思是假装正在做某事，强调动作的一个进行时态。 举例:They pretend to be reading books when the teacher sneakingly stands at the back door.当老师偷偷地站在后门的时候他们假装正在读书(读书与老师站在后门都是过去进行时 态)(JasoOon的回答) Asmanypeople do，youoftenpretend to be doingwork when actuallyyou arejust wasting time online.像很多人一样，你经常假装正在工作，其实是在上网。 群主补充：昨天和今天已提交作业的同学，做得都很好，全部授予小红花。希望你们再接再厉，不要松懈哟。所以下周一出题者为所有已提交作业的同学或者你们选出的代表。
“的、地、得”的用法教案 教学目标： 1.能通过看视频知道“的、地、得”的用法区别。 2.能在小组合作中正确掌握“的、地、得”的用法。 3.能正确熟练地运用“的、地、得”。 教学重点：通过看视频知道“的、地、得”的用法区别。 教学难点：正确熟练地运用“的、地、得”。 教学过程： 一、导入（板书课题：“的、地、得”的用法“的、地、得”） 这三个字认识吧！虽然它们都有一个相同的读音de，但用法却不一样，可不能把他们用错了。究竟他们的用法有什么不同，我们来听听他们的故事吧！ 二、看微视频，学习“的、地、得”的用法区别。 三、小结： 1.孩子们，刚才看了视频知道他们是谁吗？（白勺的，土也地，双人得。） （1）白勺的是个杂货铺老板，她的店里都有什么？（彩色的毛巾美味的汉堡结实的帐篷舒适的儿童车捕捉风的网会唱歌的小树开个没完的花朵优美动听的歌曲飘来飘去的云……）还可能有什么？ 你们一定会发现，白勺的的用法有什么特点？（后面是名词。）板书：名词 （2）土也地是个运动男孩，他喜欢？（悠闲地散步欢快地跳舞兴奋地跳跃开心地捕蝴蝶看图书踢球骑自行洗澡吃冰淇淋……）他还可能喜欢干什么呢？你发现了吗？土也地的用法特点？（后面是动词。）板书：动词 （3）双人得呢？她是个总喜欢评价别人的小妹妹。（球踢得真棒舞跳得精彩长得好高呀……） 她可能还怎么评价别人？（歌唱得动听饭吃得很饱人长得漂亮）你们会发现，双人得的前面通常都是——动词。板书：动词 2.小结：所以，他们的用法也很简单，区别就在这里。 （白勺的用在名词前面；土也地用在动词前面；双人得用在动词后面。）你明白了吗？ 四、我来考考你们，看哪一组完成得又对又快！ 1.菜鸟级练习 2.老鸟级练习 3.大虾级练习 五、总结
标点符号用法 一、标点符号 标点符号：辅助文字记录语言的符号，是书面语的有机组成部分，用来表示语句的停顿、语气以及标示某些成分（主要是词语）的特定性质和作用。 句子：前后都有较大停顿、带有一定的语气和语调、表达相对完整意义的语言单位。 复句：由两个或多个在意义上有密切关系的分句组成的语言单位，包括简单复句（内部只有一层语义关系）和多重复句（内部包含多层语义关系）。 分句：复句内两个或多个前后有停顿、表达相对完整意义、不带有句末语气和语调、有的前面可添加关联词语的语言单位。 陈述句：用来说明事实的句子。 祈使句：用来要求听话人做某件事情的句子。 疑问句：用来提出问题的句子。 感叹句：用来抒发某种强烈感情的句子。 词语：词和短语（词组）。词，即最小的能独立运用的语言单位。短语，即由两个或两个以上的词按一定的语法规则组成的表达一定意义的语言单位，也叫词组。 二、分类 标点符号分为点号和标号两大类。
点号的作用是点断，主要表示说话时的停顿和语气。点号又分为句末点号和句内点号。 句末点号用在句末，表示句末停顿和句子的语气，包括句号、问号、叹号。 句内点号用在句内，表示句内各种不同性质的停顿，有逗号、顿号、分号、冒号。 标号的作用是标明，主要标示某些成分（主要是词语）的特定性质和作用。包括引号、括号、破折号、省略号、着重号、连接号、间隔号、书名号、专名号、分隔号。 （一）句号 1.用于句子末尾，表示陈述语气。使用句号主要根据语段前后有较大停顿、带有陈述语气和语调，并不取决于句子的长短。 2.有时也可表示较缓和的祈使语气和感叹语气。 请您稍等一下。 我不由地感到，这些普通劳动者也是同样值得尊敬的。 （二）问号 主要表示句子的疑问语气。形式是“？”。 1.用于句子末尾，表示疑问语气（包括反问、设问等疑问类型）。使用问号主要根据语段前后有较大停顿、带有疑问语气和语调，并不取决于句子的长短。 2.选择问句中，通常只在最后一个选项的末尾用问号，各个选项之间一般用逗号隔开。当选项较短且选项之间几乎没有停顿时，选项之间可不用逗号。当选项较多或较长，或有意突出每个选项的独立性时，也可每个选项之后都用问号。 3.问号也有标号的用法，即用于句内，表示存疑或不详。 马致远（1250？―1321）。 使用问号应以句子表示疑问语气为依据，而并不根据句子中包含有疑问词。当含有疑问词的语段充当某种句子成分，而句子并不表示疑问语气时，句末不用问号。
英语语法顺口溜(巧记). 英语学习 动词为纲“滚雪球” 难易编组抓循环 同类归纳印象深图示介词最直观 混淆多因形音义反义词语成对念 构词方法不可忘习惯用语集中练 词不离句法最好课外阅读莫间断 be 的用法口诀 我用am，你用are，is连着他，她，它； 单数名词用is，复数名词全用are。 变疑问，往前提，句末问号莫丢弃。 变否定，更容易，be后not莫忘记。 疑问否定任你变，句首大写莫迟疑。 时间名词前所用介词的速记歌 年月周前要用in，日子前面却不行。 遇到几号要用on，上午下午又是in。 要说某日上下午，用on换in才能行。 午夜黄昏须用at，黎明用它也不错。 at也用在明分前，说“差”可要用上to， 说“过”只可使用past，多说多练牢牢记， 莫让岁月空蹉跎。 记住f(e)结尾的名词复数 妻子持刀去宰狼，小偷吓得发了慌； 躲在架后保己命，半片树叶遮目光。 巧记48个国际音标 单元音共十二，四二六前中后。 双元音也好背，合口集中八个整。 辅音共计二十八，八对一清又七浊， 四个连对也包括。有气无声清辅音， 有声无气浊辅音，发音特点应掌握。 非谓语动词的一些特殊用法后只接不定式作宾语的一些常用特殊谓语动词动词后，不定式，want, hope和wish， agree, decide, mean, manage, promise, expect, pretend,且说两位算在此， 要记牢，要记住，掌握它们靠自己。
英语学习小窍门 后接动词不定式做宾语补足语省略不定式符号“to”的一些常用特殊动词 一些动词要掌握，have, let和make, 此三动词是使役，“注意”“观察”“听到”see， 还有feel和watch，使用它们要仔细， 后接“宾补”略去“to”，此点千万要牢记 除此之外，还可以掌握“八字言”， 一感feel,二听hear, listen to, 三让have, let, make,四看see, look at, observe, watch 后只接动名词做宾语的一些常用特殊动词 特殊动词接“动名”，使用它们要记清， “放弃”“享受”可“后悔”， “坚持”“练习”必“完成”， “延期”“避免”非“介意” 掌握它们今必行。 动名词在句中的功能及其它 “动名”语法其功能，名词特征有动、形，主宾表定都可作，“动名”、“现分”要认清，“现分”不作“宾”和“主”， 动名作“状”可不行。二词皆可作定语，混为一谈不允许，主谓关系视分词，“动名”一词无此义。 现在分词形式及在句子中的作用（包括过去分词的作用）： 现在分词真好记，动词后面ING。它的作用真不小，可以充当定状表。 还有宾语补足语，忘记此项不可以。 分词做定语的位置及其它 “定分”位置有二条，词前词后定分晓。 单个分词在词前，有时此规有颠倒。 分词短语在词后，“定从”和它互对照。 “现分”动作进行时，“过分”动作完成了。 （注：“定分”：做定语的分词；“定从”：定语从句；“现分”：现在分词；“过分”：过去分词。） 分词做状语在句子中所表示的意义 分词做状语，概有七意义。“ 时间”和“原因”，“结果”与“目的”。 “方式”加“伴随”，“条件”常出席。 且谈其主语，谓语头前的*。 欲要记住它，必须常练习。（*指句子的主语）
定语从句用法分析 定语从句在整个句子中担任定语，修饰一个名词或代词，被修饰的名词或代词叫先行词。定语从句通常出现在先行词之后，由关系词（关系代词或关系副词）引出。 eg. The boys who are planting trees on the hill are middle school students 先行词定语从句 #1 关系词： 关系代词：who, whom, whose, that, which, as (句子中缺主要成份:主语、宾语、定语、表语、同位语、补语)， 关系副词：when, where, why （句子中缺次要成份：状语）。 #2 关系代词引导的定语从句 关系代词引导定语从句，代替先行词，并在句中充当主语、宾语、定语等主要成分。 1）who, whom, that 指代人，在从句中作主语、宾语。 eg. Is he the man who/that wants to see you?（who/that在从句中作主语） ^ He is the man who/whom/ that I saw yesterday.（who/whom/that在从句中作宾语） ^ 2）whose 用来指人或物，（只用作定语, 若指物，它还可以同of which互换）。eg. They rushed over to help the man whose car had broken down. Please pass me the book whose cover is green. = the cover of which/of which the cover is green. 3）which, that指代物，在从句中可作主语、宾语。 eg. The package （which / that）you are carrying is about to come unwrapped. ^ （which / that在从句中作宾语,可省略） 关系代词在定语从句中作主语时，从句谓语动词的人称和数要和先行词保持一致。 eg. Is he the man who want s to see you? #3.关系副词引导的定语从句 关系副词when, where, why引导定语从句，代替先行词（时间、地点或理由），并在从句中作状语。 eg. Two years ago, I was taken to the village where I was born. Do you know the day when they arrived? The reason why he refused is that he was too busy. 注意： 1）关系副词常常和"介词+ which"结构互换 eg. There are occasions when （on which）one must yield (屈服). Beijing is the place where（in which）I was born. Is this the reason why （for which）he refused our offer? * 2）在非正式文体中，that代替关系副词或"介词+ which"，放在时间、地点、理由的名词，在口语中that常被省略。 eg. His father died the year （that / when / in which）he was born. He is unlikely to find the place （that / where / in which）he lived forty years ago.
的、得、地的用法：动词前提土旁、动词后双人旁、一动不动白字旁 （一） 的地得，不一样，用法分别记心上， 左边白，右边勺，名词跟在后面跑。 美丽的花儿绽笑脸，青青的草儿弯下腰， 清清的河水向东流，蓝蓝的天上白云飘， 暖暖的风儿轻轻吹，绿绿的树叶把头摇， 小小的鱼儿水中游，红红的太阳当空照， 左边土，右边也，地字站在动词前， 认真地做操不马虎，专心地上课不大意， 大声地朗读不害羞，从容地走路不着急， 痛快地玩耍来放松，用心地思考解难题， 勤奋地学习要积极，辛勤地劳动花力气， 左边两人就使得，形容词前要用得， 兔子兔子跑得快，乌龟乌龟爬得慢， 青青竹子长得快，参天大树长得慢， 清晨锻炼起得早，加班加点睡得晚， 欢乐时光过得快，考试题目出得难。 （二）“的、地、得”快板 的地得、的地得，用作助词都读de. 作文写话用不准，朗读往往会念错。 有趣的活动、绿的树，活动是事，树是物。 事物前面用的字，小朋友们都记着。 认真地想、快快地跑，想跑看摸是动作。 动作前面用地字，位置千万不要挪。 看得清，记得准，唱得好，飞得高。 动作后面用得字，补充说明要记牢。 （三）“的、地、得”用法简要口诀 名词前面“白勺”“的”， 动词前面“土也”“地”， 形容动后“双人”“得”， 当作助词都读“de”。 二、“的、地、得”用法小析 “的”后面跟的都是表示事物名称的词或词语，如：敬爱的总理、慈祥的老人、戴帽子的男孩、珍贵的教科书、鸟的天堂、伟大的祖国、有趣的情节、优雅的环境、可疑的情况、团结友爱的集体、他的妈妈、可爱的花儿、谁的橡皮、清清的河水...... “地”后面跟的都是表示动作的词或词语，如：高声地喊、愉快地唱、拼命地逃、疯狂地咒骂、严密地注视、一次又一次地握手、迅速地包围、沙沙地直响、斩钉截铁地说、从容不迫地申述、用力地踢、仔细地看、开心地笑笑......” “得”前面跟的多数是表示动作的词或词语，后面跟的都是形容事物状态的词或词语，表示怎么怎么样的，如：走得很快、踩得稀烂、疼得直叫唤、瘦得皮包骨头、红得发紫、气得双脚直跳、理解得十分深刻、乐得合不拢嘴、惊讶得目瞪口呆、大得很、扫得真干净、笑得多甜啊...... 三、“的、地、得”的用法补充说明：